You explained the physiology and the different variants extensively but were quite short on the medications (what affected people would be interested most in I guess). Most significantly there is a new, promising mode of action (instead factor replacement) led by Emicizumab which is given subcutanously instead of i.v. - a milestone in patient convenience.

https://en.wikipedia.org/wiki/Emicizumab